Chicago Partners Investment Group LLC Acquires 20,249 Shares of Bristol Myers Squibb Company $BMY

Chicago Partners Investment Group LLC raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.1% in the 1st quarter, HoldingsChannel reports. The fund owned 64,146 shares of the biopharmaceutical company’s stock after acquiring an additional 20,249 shares during the period. Chicago Partners Investment Group LLC’s holdings in Bristol Myers Squibb were worth $3,772,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. waypoint wealth counsel bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb during the fourth quarter valued at $34,406,000. Axxcess Wealth Management LLC boosted its position in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after acquiring an additional 21,196 shares during the last quarter. Daytona Street Capital LLC acquired a new stake in Bristol Myers Squibb during the 4th quarter worth about $1,362,000. Finally, Pensionfund Sabic bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $1,845,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 3.0%

BMY stock opened at $59.31 on Tuesday. The stock’s 50 day simple moving average is $56.80 and its 200 day simple moving average is $57.67. The company has a market cap of $121.12 billion, a P/E ratio of 16.66, a price-to-earnings-growth ratio of 0.16 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on BMY shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. HSBC boosted their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $61.25.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.